INTRODUCTION
STUDY GOAL AND OBJECTIVES
CONTRIBUTION OF THE STUDY AND FOR WHOM
STUDY SCOPE AND FORMAT
METHODOLOGY
INFORMATION SOURCES
ANALYST'S CREDENTIALS
RELATED BCC WORK CREDENTIALS INCLUDING WORK DONE BY OTHER AUTHORS
BCC ONLINE SERVICES
DISCLAIMER
SUMMARY
Summary Table:
WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC IMAGING ANTIBODIES, THROUGH 2010 ($ MILLIONS)
Summary Figure:
WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC IMAGING ANTIBODIES, 2002-2010 ($ MILLIONS)
OVERVIEW
DEFINITIONS
THE IMPORTANCE OF ANTIBODY DRUGS AND DIAGNOSTICS
INTELLECTUAL PROPERTY ISSUES/PATENT LICENSING
THE TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS
Table 1 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS
ADVANTAGES OF MONOCLONAL ANTIBODY DRUGS
WHY DO MONOCLONAL ANTIBODY PRODUCTS HAVE SO MANY APPLICATIONS AND POLYCLONAL ANTIBODY PRODUCTS DO NOT?
VALUATION OF ANTIBODY PRODUCT SALES
TECHNOLOGY
OVERVIEW
THE HAMA PROBLEM AND ITS RESOLUTION
PHAGE DISPLAY AND POLYSOME DISPLAY
DIRECTED EVOLUTION
ANTIBODY CLASSES
ANTIBODY FORMS IN PRODUCTS
ABTIDES
ANTIBODY CONJUGATES
ANTISERUMS
BISPECIFIC ANTIBODIES
CAMOUFLAGED ANTIBODIES
CHIMERIC ANTIBODIES
FULLY HUMAN ANTIBODIES
HUMANIZED ANTIBODIES
PROGENITOR STEM CELLS
SINGLE-CHAIN ANTIBODIES
SYNTHETIC ANTIBODIES
SOURCES OF MONCLONAL ANTIBODIES ON THE MARKET
Table 2 MARKETED MONOCLONAL ANTIBODY PRODUCTS AND THEIR SOURCES
THE SPECIAL CASE OF ENBREL
ANTIBODY TECHNOLOGIES IN DEVELOPMENT
AFFIBODIES
DOMAIN ANTIBODIES
NANOBODIES
NEW DIRECTIONS IN ANTIBODY RESEARCH
THE MARKET OPPORTUNITY FOR TRANSGENIC PRODUCTION OF ANTIBODY PRODUCTS
THE HIGH COST OF PRODUCING ANTIBODIES AND OTHER PROTEIN DRUGS
THE GROWING CRISIS IN MEETING PRODUCTION DEMANDS FOR PROTEIN DRUGS
Table 3 U.S. DEMAND FOR BIOLOGICS, THROUGH 2010 ($ MILLIONS)
Table 4 MONOCLONAL ANTIBODY BIOPROCESSING MARKET: U.S., THROUGH 2010 ($ MILLIONS)
THE TRANSGENIC ADVANTAGE
TRADITIONAL PRODUCTION METHODS
MICROBIAL FERMENTATION
MAMMALIAN CELL CULTURE
Table 5 SELECTED PROTEIN DRUGS AND THEIR SOURCE CELLS
Table 6 ESTIMATED CAPACITY REQUIREMENTS FOR SELECTED CURRENTLY MARKETED PROTEIN PRODUCTS
Table 7 ESTIMATED MAMMALIAN CELL CULTURE MANUFACTURING CAPACITIES FOR SELECTED COMPANIES
THE ENBREL SHORTAGE
THE CRUNCH IN CAPACITY
REASONS FOR THE NEED TO INCREASE PROTEIN DRUG PRODUCTION
GENOMICS AND GENE DISCOVERY DRIVE THE EXPANDING DEVELOPMENT OF PROTEIN DRUGS
PRODUCTION OF ANTIBODIES IN ANIMALS
GOATS AS MONOCLONAL ANTIBODIES FACTORIES
CHICKENS AS MONOCLONAL ANTIBODIES FACTORIES
PRODUCTION OF ANTIBODIES IN PLANTS
PLASTIDS
TARGETING AND COMPARTMENTALIZING
TRANSGENIC SEEDS FOR ANTIBODY STORAGE
THE MARKET FOR TRANSGENICALLY PRODUCED ANTIBODY PRODUCTS
Table 8 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS)
Figure 1 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS)
PLANTIBODIES IN DEVELOPMENT
Table 9 THERAPEUTIC PLANTIBODIES: APPLICATION AND SPECIFICITY, SIGNAL SEQUENCES AND PLANT SOURCE
ANTI-RABIES ANTIBODIES
CARORX
CLOSTRIDIUM DIFFICILE TOXIN A AND TOXIN B
OTHER THERAPEUTIC PLANTIBODIES IN DEVELOPMENT
TECHNOLOGY ISSUES WITH PLANT-BASED HUMAN ANTIBODIES
USING MONOCLONAL ANTIBODIES AS CARRIERS FOR CYTOTOXIC DRUGS
CONTRACT MANUFACTURING MARKET FOR BIOPHARMACEUTICALS GROWING
Table 10 U.S. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, THROUGH 2010 ($ MILLIONS)
PRODUCTS
THE MARKET FOR POLYCLONAL AND MONOCLONAL ANTIBODY DRUGS
Table 11 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, THROUGH 2010 ($ MILLIONS)
Figure 2 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, 2002-2010 ($ MILLIONS)
THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS
THE MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES
Table 12 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
Sales by Technology
Table 13 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, THROUGH 2010 ($ MILLIONS)
Figure 3 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, 2002-2010 ($ MILLIONS)
Sales by Target
Table 14 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET: WORLDWIDE, THROUGH 2010 ($ MILLIONS)
THE U.S. MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES
Table 15 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: U.S., THROUGH 2010 ($ MILLIONS)
Marketed Products
Table 16 MONOCLONAL ANTIBODY PRODUCTS ON THE U.S. MARKET
THE EUROPEAN MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODIES
Table 17 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: EUROPE, THROUGH 2010 ($ MILLIONS)
Marketed Products
Table 18 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET
Avastin
The Avastin Advantage
New Medicare Reimbursement Law Supports Use of Avastin
Bexxar
Campath/MabCampath
Erbitux
Table 19 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
Table 20 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
Herceptin
Humira
Mylotarg
Orthoclone OKT3
Panorex
Raptiva
Remicade
ReoPro
Rituxan/MabThera
Simulect
Synagis
Tysabri (formerly Antegren)
Xolair
Zenapax
Zevalin
First Radioimmunotherapeutic Drug
Results of Trials
Sales of Zevalin
THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS IN DEVELOPMENT
Table 21 MONOCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
ABT-874
AMG 108
AMG 162
AMG 714
Anti-CD20 Humanized Anticlonal Antibody
Anti-Tac(Fv)-PE38 Immunotoxin
Anti-TGF Beta
Avastin
CAL
Campath
Cantuzumab Mertansine
CAT-192
Cimzia (formerly CDP-870)
Cotara
Eculizumab
Erbitux
Felvizumab
Herceptin
HuMax-CD4
HuMax-CD20
HuMax-EGFr
HuMax-Inflam
Humira
HuN901-DM1
HuZAF
IMMU-102 and IMMU-103
Lucentis
LymphoStat-B
M200
MDX-010
MDX-018
MDX-060
MDX-070
Mepolizumab
MLN 02
MLN 1202
MLN 2704
Numax
Nuvion
Omnitarg
Osidem
OvaRex
Panitumumab
Pemtumomab
Pexelizumab
Pro70769
R1569
Remicade
Rituxan/MabThera
SGN-15
SGN-30
Synagis
TheraCIM hR3
Trabio
Tysabri
Vitaxin
Xolair
Zenapax
THERAPEUTIC POLYCLONAL ANTIBODY PRODUCTS
IMMUNOGLOBULINS
Intramuscular Products
Intravenous Products
NEW APPROACHES TO THE PRODUCTION OF HUMAN POLYCLONAL ANTIBODIES
THE MARKET FOR THERAPEUTIC POLYCLONAL ANTIBODY PRODUCTS
Table 22 POLYCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
MARKETED PRODUCTS
ATG-Fresenius S
BabyBIG
CytoGam
Flebogamma
Gamimune
Gamunex
Nabi-HB
Octagam
Rabies Immune Globulin
RespiGam
Tetanus Immune Globulin
Vaccinia Immune Globulin
Varicella-Zoster Immune Globulin
WinRho SDF Rho(D) Immune Globulin
Anti-Thymocyte Globulin
Atgam
Thymoglobulin
Antitoxins and Antivenins
CroFab
DigiFab
Diphtheria Antitoxin
ViperTAb
PRODUCTS IN DEVELOPMENT
Table 23 POLYCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
Altastaph
ATG-Fresenius S
CytoFab
Nabi-HB Intravenous
Thymoglobulin
WinRho SDF
Early-Stage Products in Development
IN VIVO DIAGNOSTIC ANTIBODY PRODUCTS
Table 24 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
Figure 4 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, 2002-2010 ($ MILLIONS)
MARKETED PRODUCTS
CEA-Scan
Humaspect
LeukoScan
MIBG
MyoScint
NeutroSpec
OctreoScan
ProstaScint
Verluma
PRODUCTS IN DEVELOPMENT
Table 25 DIAGNOSTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
AFP-Scan
Blood Tumor Antibody Diagnostics
CEA-Scan
LeukoScan
LymphoScan
NeutroSpec
ProstaScint
Tru-Scint AD
Tru-Scint AG
APPLICATIONS
LEADING THERAPEUTIC INDICATIONS OF APPROVED MONOCLONAL THERAPEUTIC ANTIBODY PRODUCTS
Table 26 APPLICATIONS OF THERAPEUTIC MONOCLONAL ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
Figure 5 WORLDIWDE THERAPEUTIC MONOCLONAL ANTIBODIES, PERCENTAGE OF MARKET BY APPLICATION, 2004 AND 2010 (%)
AUTOIMMUNE DISEASES
Crohn's Disease
Psoriasis
Rheumatoid Arthritis
Antibody Products on the Market for the Treatment of Autoimmune Diseases
Table 27 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
Antibodies in Development for the Treatment of Autoimmune Diseases
Table 28 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF AUTOIMMUNE DISEASES
CANCER
U.S. Cancer Statistics
Table 29 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS: U.S., 2004 (ESTIMATED)
Table 30 CANCER PREVALENCE RATES: U.S., 2000
Breast Cancer
Colorectal Cancer
Head and Neck Cancer
Kidney Cancer
Leukemias
Liver Cancer
Lung Cancer
Malignant Melanoma
NonHodgkin's Lymphoma
Osteosarcoma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Stomach Cancer
Antibody Products on the Market for the Treatment of Cancer
Table 31 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER
Antibodies in Development for the Treatment of Cancer
Table 32 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SPECIFIC CANCERS
CARDIOVASCULAR DISEASES
Table 33 ESTIMATED INPATIENT CARDIOVASCULAR PROCEDURES, U.S., 2002
Percutaneous Transluminal Coronary Angioplasty
Antibody Products on the Market for the Treatment of Cardiovascular Disease
Antibodies in Development for the Treatment of Cardiovascular Diseases
Table 34 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
INFECTIOUS DISEASES
Cytomegalovirus Infection
Hepatitis
Respiratory Syncytial Virus Infection
Antibodies on the Market for the Treatment of Infectious Diseases
Antibodies in Development for the Treatment of Infectious Diseases
Table 35 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFECTIOUS DISEASES
OPHTHALMIC DISEASES
Macular Degeneration
ORGAN TRANSPLANT REJECTION AND GRAFT-VERSUS-HOST DISEASE
Organ Transplant Market Size
Table 36 U.S. ORGAN TRANSPLANTS BY TYPE, 1997 TO 2004
Antibody Products on the Market for the Treatment of Organ Transplant Rejection
Table 37 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF ORGAN TRANSPLANT REJECTION
Antibodies in Development for Organ Transplant Rejection
Table 38 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE PREVENTION OF ORGAN TRANSPLANT REJECTION
Bone Marrow and Stem Cell Transplantation/Graft-Versus-Host Disease
Table 39 GRAFT-VERSUS-HOST DISEASE: WORLDWIDE INCIDENCE, 1998-2004
RESPIRATORY DISEASES
Allergic Rhinitis and Asthma
Antibody Products on the Market for the Treatment of Allergic Rhinitis and Asthma
Antibodies in Development for the Treatment of Allergic Rhinitis and Asthma
Table 40 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ALLERGIC RHINITIS AND/OR ASTHMA
OTHER THERAPEUTIC APPLICATIONS
Table 41 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SELECTED OTHER DISEASES
DIAGNOSTIC IMAGING APPLICATIONS
IN VIVO DIAGNOSTIC IMAGING ANTIBODY PRODUCTS IN DEVELOPMENT FOR SELECTED INDICATIONS
Table 42 IN VIVO DIAGNOSTIC IMAGING ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR SELECTED INDICATIONS
INDUSTRY STRUCTURE
ORIGINATORS
COMMERCIAL DEVELOPERS
VENDORS
MANUFACTURERS
TECHNOLOGY INNOVATORS
PRICING FORECASTS
PARTNERSHIPS ABOUND
Table 43 SELECTED ANTIBODY PRODUCT DEVELOPMENT PARTNERSHIPS FORMED IN 2003 AND 2004
THE REGULATORY ENVIRONMENT
MARKET SHARE OF MONOCLONAL ANTIBODY PRODUCT MANUFACTURERS
Figure 6 MARKET SHARE OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY MANUFACTURER, 2004 (%)
GENOMICS AND MONOCLONAL ANTIBODIES: A MATCH FOR SUCCESS
COMPANY PROFILES
ABGENIX, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
XenoMouse and XenoMax Technologies
Technology Advantages
CORPORATE STRATEGY
AMGEN, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
Table 44 AMGEN'S MONOCLONAL ANTIBODY PRODUCT PIPELINE
CORPORATE STRATEGY
BIOGEN IDEC, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
BUSINESS OVERVIEW
PRODUCTS
CORPORATE STRATEGY
CORIXA CORP.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
CYTOGEN CORPORATION
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
GENENTECH, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
Table 45 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
Table 46 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
GENMAB A/S
BUSINESS OVERVIEW
PRODUCTS
CORPORATE STRATEGY
GENZYME CORPORATION
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
Table 47 GENZYME'S MONOCLONAL ANTIBODY PRODUCT PIPELINE
CORPORATE STRATEGY
GTC BIOTHERAPEUTICS
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS AND TECHNOLOGIES
Monoclonal Antibodies (MAB) and Immunoglobulin (Ig) Fusion Proteins
CORPORATE STRATEGY
IMMUNOMEDICS, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
Table 48 IMMUNOMEDICS' PRODUCT PIPELINE
CORPORATE STRATEGY
MEDAREX, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
Table 49 MEDAREX'S PRODUCT PIPELINE
CORPORATE STRATEGY
MEDIMMUNE, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
LEADING PRODUCTS
Table 50 MEDIMMUNE'S MONOCLONAL ANTIBODY PRODUCT PIPELINE
CORPORATE STRATEGY
MILLENNIUM PHARMACEUTICALS, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
Table 51 MILLENNIUM'S MONOCLONAL ANTIBODY PRODUCT PIPELINE
CORPORATE STRATEGY
NABI BIOPHARMACEUTICALS
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
Table 52 NABI BIOPHARMACEUTICALS' PRODUCT PIPELINE
CORPORATE STRATEGY
PLANET BIOTECHNOLOGY, INC.
BUSINESS OVERVIEW
PRODUCTS AND TECHNOLOGY
CaroRx
RhinoRx
DoxoRx
PROTEIN DESIGN LABS
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
Table 53 PROTEIN DESIGN LABS' MONOCLONAL ANTIBODY PRODUCT PIPELINE
CORPORATE STRATEGY
PROTHERICS PLC
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
SYMPHOGEN A/S
BUSINESS OVERVIEW
PRODUCTS
Table 54 COMPARISON OF SYMPHOBODIES, OLIGOCLONAL ANTIBODIES AND MONOCLONAL ANTIBODIES
CORPORATE STRATEGY
TRANXENOGEN, INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS AND TECHNOLOGY
CORPORATE STRATEGY
VIREXX MEDICAL CORPORATION
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
XOMA LTD.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
CORPORATE STRATEGY
YM BIOSCIENCES INC.
BUSINESS OVERVIEW
FINANCIAL INFORMATION
PRODUCTS
Table 55 YM BIOSCIENCE'S PRODUCT PIPELINE
CORPORATE STRATEGY
LIST OF TABLES
Summary Table:
WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC IMAGING ANTIBODIES, THROUGH 2010 ($ MILLIONS)
Table 1 TIMELINE TO COMMERCIALIZATION OF MONOCLONAL ANTIBODY PRODUCTS
Table 2 MARKETED MONOCLONAL ANTIBODY PRODUCTS AND THEIR SOURCES
Table 3 U.S. DEMAND FOR BIOLOGICS, THROUGH 2010 ($ MILLIONS)
Table 4 MONOCLONAL ANTIBODY BIOPROCESSING MARKET: U.S., THROUGH 2010 ($ MILLIONS)
Table 5 SELECTED PROTEIN DRUGS AND THEIR SOURCE CELLS
Table 6 ESTIMATED CAPACITY REQUIREMENTS FOR SELECTED CURRENTLY MARKETED PROTEIN PRODUCTS
Table 7 ESTIMATED MAMMALIAN CELL CULTURE MANUFACTURING CAPACITIES FOR SELECTED COMPANIES
Table 8 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS)
Table 9 THERAPEUTIC PLANTIBODIES: APPLICATION AND SPECIFICITY, SIGNAL SEQUENCES AND PLANT SOURCE
Table 10 U.S. BIOPHARMACEUTICALS CONTRACT MANUFACTURING MARKET, THROUGH 2010 ($ MILLIONS)
Table 11 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, THROUGH 2010 ($ MILLIONS)
Table 12 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
Table 13 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, THROUGH 2010 ($ MILLIONS)
Table 14 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TARGET: WORLDWIDE, THROUGH 2010 ($ MILLIONS)
Table 15 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: U.S., THROUGH 2010 ($ MILLIONS)
Table 16 MONOCLONAL ANTIBODY PRODUCTS ON THE U.S. MARKET
Table 17 THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS: EUROPE, THROUGH 2010 ($ MILLIONS)
Table 18 MONOCLONAL ANTIBODY PRODUCTS ON THE EUROPEAN MARKET
Table 19 RANGE OF EGFR EXPRESSION IN SOLID TUMORS
Table 20 EGFR IN PROGNOSIS FOR SELECTED TUMOR TYPES
Table 21 MONOCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
Table 22 POLYCLONAL ANTIBODY PRODUCTS: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
Table 23 POLYCLONAL ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
Table 24 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
Table 25 DIAGNOSTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT
Table 26 APPLICATIONS OF THERAPEUTIC MONOCLONAL ANTIBODIES: WORLDWIDE SALES, THROUGH 2010 ($ MILLIONS)
Table 27 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES
Table 28 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF AUTOIMMUNE DISEASES
Table 29 INCIDENCE, MORTALITY, AND SURVIVAL RATES FOR COMMON CANCERS: U.S., 2004 (ESTIMATED)
Table 30 CANCER PREVALENCE RATES: U.S., 2000
Table 31 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF CANCER
Table 32 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SPECIFIC CANCERS
Table 33 ESTIMATED INPATIENT CARDIOVASCULAR PROCEDURES, U.S., 2002
Table 34 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF CARDIOVASCULAR DISEASES
Table 35 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF INFECTIOUS DISEASES
Table 36 U.S. ORGAN TRANSPLANTS BY TYPE, 1997 TO 2004
Table 37 MARKETED MONOCLONAL ANTIBODY PRODUCTS FOR THE TREATMENT OF ORGAN TRANSPLANT REJECTION
Table 38 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE PREVENTION OF ORGAN TRANSPLANT REJECTION
Table 39 GRAFT-VERSUS-HOST DISEASE: WORLDWIDE INCIDENCE, 1998-2004
Table 40 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF ALLERGIC RHINITIS AND/OR ASTHMA
Table 41 THERAPEUTIC ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR THE TREATMENT OF SELECTED OTHER DISEASES
Table 42 IN VIVO DIAGNOSTIC IMAGING ANTIBODY PRODUCTS IN PHASE II OR LATER DEVELOPMENT FOR SELECTED INDICATIONS
Table 43 SELECTED ANTIBODY PRODUCT DEVELOPMENT PARTNERSHIPS FORMED IN 2003 AND 2004
Table 44 AMGEN'S MONOCLONAL ANTIBODY PRODUCT PIPELINE
Table 45 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
Table 46 SELECTED PRODUCTS FROM WHICH GENENTECH RECEIVES ROYALTIES
Table 47 GENZYME'S MONOCLONAL ANTIBODY PRODUCT PIPELINE
Table 48 IMMUNOMEDICS' PRODUCT PIPELINE
Table 49 MEDAREX'S PRODUCT PIPELINE
Table 50 MEDIMMUNE'S MONOCLONAL ANTIBODY PRODUCT PIPELINE
Table 51 MILLENNIUM'S MONOCLONAL ANTIBODY PRODUCT PIPELINE
Table 52 NABI BIOPHARMACEUTICALS' PRODUCT PIPELINE
Table 53 PROTEIN DESIGN LABS' MONOCLONAL ANTIBODY PRODUCT PIPELINE
Table 54 COMPARISON OF SYMPHOBODIES, OLIGOCLONAL ANTIBODIES AND MONOCLONAL ANTIBODIES
Table 55 YM BIOSCIENCE'S PRODUCT PIPELINE
LIST OF FIGURES
Summary Figure:
WORLDWIDE SALES OF THERAPEUTIC AND DIAGNOSTIC IMAGING ANTIBODIES, 2002-2010 ($ MILLIONS)
XXV
Figure 1 TRANGENICALLY PRODUCED THERAPEUTIC PROTEIN MARKET: ESTIMATED WORLDWIDE SALES OF SELECTED MONOCLONAL ANTIBODIES, 2008-2013 ($ MILLIONS)
Figure 2 WORLDWIDE SALES OF MONOCLONAL AND POLYCLONAL ANTIBODIES AS DRUGS, 2002-2010 ($ MILLIONS)
Figure 3 MARKET FOR THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY TECHNOLOGY: WORLDWIDE, 2002-2010 ($ MILLIONS)
Figure 4 DIAGNOSTIC IMAGING ANTIBODIES: WORLDWIDE SALES, 2002-2010 ($ MILLIONS)
Figure 5 WORLDIWDE THERAPEUTIC MONOCLONAL ANTIBODIES, PERCENTAGE OF MARKET BY APPLICATION, 2004 AND 2010 (%)
Figure 6 MARKET SHARE OF THERAPEUTIC MONOCLONAL ANTIBODY PRODUCTS BY MANUFACTURER, 2004 (%)
